Frier Levitt has recently become aware that the New Jersey Department of Health (NJDOH) has been issuing notices to medical practices and other facilities that may offer Platelet-Rich Plasma (PRP) injections to patients for non-surgical purposes –... Read More
After DEA’s of its draft temporary rule last week, the Drug Enforcement Administration (“DEA”) has officially published a temporary rule expanding COVID-19 related flexibilities for prescribing controlled substances via telehealth. The... Read More
Beginning in March 2020 with the shutdown orders effectuated by Governor Phil Murphy, the various licensing boards organized under the State of New Jersey, Division of Consumer Affairs, experienced a significant decrease in activity. The state was... Read More
Continuing its aggressive efforts to combat fraud, waste and abuse in the health care system, the Federal government has focused on providers’ practices related to the disposing of and billing for single-use drugs and biological waste. Frier... Read More
Last month, HHS Office for Civil Rights (“OCR”) announced that its COVID-19 related enforcement discretion regarding the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) will end on May 11, 2023, coinciding with the... Read More
Fraud is a persistent issue in the history of U.S. healthcare. However, with the government’s decreased oversight and the implementation of telehealth billing codes and diagnostic abilities during the COVID-19 pandemic, new opportunities for... Read More
Last month, Cerebral, Inc., notified the Department of Health and Human Services Office for Civil Rights (“OCR”), and issued a public notice, that nearly 3.2 million individuals may have been affected by a breach of data, including protected... Read More
Frier Levitt attorneys speak with prosecutors, Boards of Pharmacies, PBM auditors, wholesalers, and the like on a daily basis on behalf of pharmacies nationally. We regularly spot trends and report back to the industry. We are closely monitoring... Read More
The healthcare and life science industries should be aware of the recent increase in False Claims Act (“FCA”) or “whistleblower” cases. In fiscal year 2022, the Department of Justice (“DOJ”) recovered $2.2 billion under the FCA. In 2021,... Read More
In the wake of the Federal Trade Commission (“FTC”) enforcement action against GoodRx last month, the agency has issued another proposed consent order against virtual mental health platform BetterHelp on a similar basis. Namely, the... Read More
